HOME >> BIOLOGY >> NEWS
Clemson researcher receives Komen grant

CLEMSON A Clemson University scientist has received $250,000 to pursue a promising line of research for a way to treat breast cancer. Wen Y. Chen, associate professor in Clemson's department of biological sciences and assistant director of the Oncology Research Institute of Greenville Hospital System, has received funding from the prestigious Susan G. Komen Breast Cancer Foundation in Dallas. He is the first scientist from South Carolina to receive a Komen Foundation grant. Chen will use the money to further his research on stopping breast cancer cells from developing.

"We are excited and grateful for this grant," said Chen. "It signals that we are on the right track. In the past five years, we have focused on developing a potential treatment for breast cancer. With this grant we can move ahead on testing whether the combination approach will significantly improve the existing treatment in an aggressive subtype of breast cancer."

Scientists have learned that human prolactin (PRL), a hormone normally produced in the brain and mainly responsible for mammary gland development and milk production, may be involved in breast cancer development.

"The involvement of PRL in breast cancer is likely due to, in some cases, the fact that mutated breast cells produce PRL as their own survival-growth factor, which keeps most growth signal at "on" position," said Chen. "This self-sustained, vicious growth ability eventually leads to cancer formation."

To "turn off" these growth signals induced by PRL, scientists set out to develop a counteragent -- an antagonist. Working with his colleagues and graduate students at the Oncology Research Institute, Chen has demonstrated that a mutated PRL, called PRL antagonist (G129R), is able to bind specifically to breast cancer cells and block the effect of PRL, inhibiting tumor growth in mice. What's more, the PRL antagonist has synergistic effects with the breast cancer drug Herceptin, which has only 30 percent response
'"/>

Contact: Wen Y. Chen
wenc@clemson.edu
864-455-1457
Clemson University
28-May-2004


Page: 1 2

Related biology news :

1. Clemson University spin-off uses corn to make plastics, provide cleaner air
2. Clemson researcher places hope on pushy photons
3. Clemson University researcher reaches for the stars to prevent osteoporosis
4. Clemson launches S.C. DNA Learning Center
5. Clemson dedicates biotech research complex
6. Breakthrough Clemson research appears in Science
7. Clemson researcher takes part in breakthrough research on insects
8. Clemson researchers find bacteria fighter that does not promote bacterial resistance
9. Clemson researchers identify mental retardation gene
10. Clemson researchers create biosensors to protect nations food and water supplies
11. Clemson-led team makes breakthrough in controlling Bt resistance in pests

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/19/2020)... ... ... Join experts from Envigo Lauren Klaskala, Project Manager – Custom Transgenic ... Wednesday, July 8, 2020 at 11am EDT (4pm BST/UK). , Nuclease-based technologies such as ... modifying the genome may be more straightforward, the challenge to create an optimal model ...
(Date:6/11/2020)... , ... June 09, 2020 , ... Superior Controls, ... industrial automation and IT solutions for the life sciences industry, is pleased to announce ... Development working out of the company’s Seabrook, New Hampshire office. In his new ...
(Date:6/5/2020)... ... ... Greffex, a pioneering vaccine and gene therapy company based in Houston, Texas, welcomes ... a global perspective to make an impact in a post pandemic world,” said Co-Chairman ... independent, director of the company. , “The Greffex board is excited to have Neil ...
Breaking Biology News(10 mins):
(Date:6/28/2020)... ... ... The Indoor Lab, a leading provider of sensor solutions for monitoring foot ... ensure cleanliness, distancing and occupancy with its patent pending WipeAway™ technology using Artificial Intelligence ... a health performance index system that scores all aspects of compliance similar to the ...
(Date:6/23/2020)... ... June 23, 2020 , ... Kerafast Inc. , developers ... announced the availability of the Delta-G-VSV Pseudotyping System for coronavirus research applications. The ... of SARS-CoV-2 viral entry and COVID-19 vaccine effectiveness at just biosafety level 2 ...
(Date:6/23/2020)... ... June 23, 2020 , ... Nobilis ... announced that it has filed an Investigational New Drug application (IND) with the ... of its lead drug candidate NBTX-001 in patients with panic disorder (PD). , ...
(Date:6/11/2020)... ... June 09, 2020 , ... TRX Systems, developer of ... Solution, a highly accurate, contact tracing solution for identification of employees who ... a core disease control measure, is a key strategy for preventing further spread ...
Breaking Biology Technology:
Cached News: